Non-Coding RNA-Targeted Therapy: A State-of-the-Art Review.
Francesco NappiPublished in: International journal of molecular sciences (2024)
The use of non-coding RNAs (ncRNAs) as drug targets is being researched due to their discovery and their role in disease. Targeting ncRNAs, including microRNAs (miRNAs) and long non-coding RNAs (lncRNAs), is an attractive approach for treating various diseases, such as cardiovascular disease and cancer. This seminar discusses the current status of ncRNAs as therapeutic targets in different pathological conditions. Regarding miRNA-based drugs, this approach has made significant progress in preclinical and clinical testing for cardiovascular diseases, where the limitations of conventional pharmacotherapy are evident. The challenges of miRNA-based drugs, including specificity, delivery, and tolerability, will be discussed. New approaches to improve their success will be explored. Furthermore, it extensively discusses the potential development of targeted therapies for cardiovascular disease. Finally, this document reports on the recent advances in identifying and characterizing microRNAs, manipulating them, and translating them into clinical applications. It also addresses the challenges and perspectives towards clinical application.
Keyphrases
- cardiovascular disease
- long non coding rna
- current status
- poor prognosis
- papillary thyroid
- cardiovascular events
- type diabetes
- cardiovascular risk factors
- adverse drug
- small molecule
- drug induced
- multidrug resistant
- open label
- squamous cell
- high throughput
- emergency department
- climate change
- clinical trial
- cell therapy
- bone marrow
- coronary artery disease
- drug delivery
- network analysis
- transcription factor
- placebo controlled